OctreoScan

In-111 Pentreotide (OctreoScan)

This radiotracer, which binds preferentially to somatostatin receptor, is used to localize PNET tumors.

Go back to Oncology (Nuclear) imaging.

Normal biodistribution

4 hours after tracer injection: Blood pool, normal thyroid, kidneys and bladder, liver, gallbladder, spleen

24 hours after tracer injection: Blood pool, normal thyroid, kidneys and bladder, liver, gallbladder, spleen, and bowel (as seen in the image above)

Image
Courtesy of SLEH

Patient Preparation

Octreotide acetate therapy should be discontinued 1 day if standard preparation, or 4 weeks if long acting/slow-release, before In-111 pentetreotide is administered.

Protocol

SNM Procedure Guideline for Somatostatin Receptor Scintigraphy 2.0 (ver 2.0, 2011)

Notes

Pheochromocytoma has classically hyperintense signal on T2W MR images.
- RM at Endocrinology MDTB in 7/2014

This site is educational in nature and for nuclear medicine, radiology and medical professionals in the U.S., contains user contributed content, and material that may be confusing to a lay audience. Readers are asked to check the most current information on nuclear medicine techniques as this website may not be all-encompassing or up-to-date. It is solely the responsibility of the professional to practice nuclear medicine based on his or her experience and knowledge of the patient. To the fullest extent of the law, neither the publisher or authors assume any liability for any consequences to persons or property arising out of or related to any use of the material in this website.